Home>News>Company News

Immune checkpoints proteinsTime:2020-07-29

Immune checkpoints are regulators that can inhibit or activate our immune system. They play essential roles in maintaining immune tolerance and modulating the duration and strength of immune responses. Cancer cells can exploit inhibitory pathways to evade the attack from immune system, especially antigen-specific T cell responses.


(Source: Reference[1])

In recent years, FDA has approved a number of therapeutic monoclonal antibody drugs that target on the inhibitory pathway of immune checkpoints, such as OPDIVO, KEYTRUDA, Ipilimumab, etc. Comparing with traditional Chemotherapy, radiation therapy or targeted therapy, the clinical benefits of immune therapy treatment are astonishing. Pharmaceutical companies start to adjust their R&D pipelines and put more resources on immune checkpoint projects.

To help customers accelerate their study on immune checkpoint targets, DIMA BIOTECH developed a series of high-quality recombinant proteins on immune checkpoint targets . All these proteins are manufactured in HEK293 cells. It is very likely that these recombinant proteins will maintain three-dimensional structure close to native proteins and the authentic post-translational modifications specific to human cells.


Part of our product

For DIMA BIOTECH, one of our long term goals is to  provide biologically active recombinant proteins for all immune checkpoint targets. Here we would like to encourage you to nominate targets that you would like to prioritize in our development pipeline.


Product Features:

Focus on developing proteins with bioactivity

1. Protein purity evaluation:

Figure 1.A) Human SIRPα, hFc-His Tag on SDS-PAGE under reducing condition(PME100009). B) Human CD47, mFc-His Tag on SDS-PAGE under reducing condition(PME100008).

2. Ligand-receptor interaction evaluation:

Figure 2. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human CD47, mFc-His tagged protein (PME100008) can bind its native ligand Human SIRPα, hFc-His tagged protein (PME100009) in a linear range of 3.3-26.37 ng/ml.

3. Biosimilar antibody interaction evaluation



Figure 3. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human CD47, mFc-His tagged protein (PME100008) can bind Anti-CD47 (Neutralizing antibody clone Hu5F9-G4)(BME100001) in a linear range of 0.061-1.606 ng/ml.


Rigorous quality testing

Every batch of recombinant proteins are under rigorous quality testing to make sure the protein stability.

1. Stability test 1: Ligand-receptor interaction testing after multiple freeze-thaw cycles


Figure 4. Human SIRPα, hFc-His tagged protein without freeze-thaw treatment. B: Human SIRPα, hFc-His tagged protein after one freeze-thaw cycle. C: Human SIRPα, hFc-His tagged protein after three freeze-thaw cycles. D: Human SIRPα, hFc-His tagged protein after five freeze-thaw cycles.

2. Stability test2: Protein integrity analysis after multiple freeze-thaw cycles


Figure 5. Lane 1: Human SIRPα, hFc-His tagged protein without freeze-thaw treatment, Lane 2: Human SIRPα, hFc-His tagged protein after one freeze-thaw cycle, Lane 3: Human SIRPα, hFc-His tagged protein after three freeze-thaw cycles, Lane 4: Human SIRPα, hFc-His tagged protein after five freeze-thaw.


Research grade biosimilar antibody promotion:

With DIMA’s biosimilar antibodies for research, you can study the biological effects of therapeutic antibody drugs without large spending on thereutic grade products. We have validated all these  research grade biosimilar products with their target proteins.

1. The ELISA binding testing of Cobolimab biosimilar antibody and recombinant TIM3 protein

 

Figure 6. ELISA plate pre-coated by 2 ug/ml (100 ul/well) Human TIM3, mFc-His tagged protein (PME100030) can bind Anti-TIM3 Neutralizing antibody (Cobolimab) in a linear range of 0.24-7.81 ng/ml.


Recombinant biosimilar antibody products:

Therapeutic Antibody
Antibody Specificity
DIMA catalog#
Magrolimab
Anti-CD47 mAb
BME100001
Elotuzumab
Anti-CS1 mAb
BME100002
Talacotuzumab
Anti-CD123 mAb
BME100003
Daratumumab
Anti-CD38 mAb
BME100004
Vorsetuzumab
Anti-CD70 mAb
BME100005
Pembrolizumab
Anti-PD-1 mAb
BME100006
Siltuximab
Anti-IL6 mAb
BME100007
Cobolimab
Anti-TIM-3 mAb
BME100008

Buy recombinant proteins with free biosimilar antibodies, please contact us for the details.

 Email: info@dimabio.com


Reference

[1]Baumeister, Susanne H., et al. "Coinhibitory pathways in immunotherapy for cancer." Annual Review of  immunology 34 (2016): 539-573.